Kodiak Sciences Inc

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$29.61+$3.59 (+13.80%)

Jun 8, 2026

52W High $46.4452W Low $3.53

Company Details

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-va...

CEO

—

IPO Date

Oct 4, 2018

Website

kodiak.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$231M

EPS (Diluted)

Free Cash Flow

-$148M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 7, 2026

FY 2025

Mar 31, 2026

Q4 2025

Mar 31, 2026

$0-100.0%

Q3 2025

Nov 13, 2025

Q2 2025

Aug 13, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee